Zusammenfassung
Um die traditionelle und berühmte „Stecknadel im Heuhaufen“ zu den Behandlungsmöglichkeiten bei einer Krankheit zu erfassen, ist es erforderlich, im ersten Schritt einen Überblick über das existierende Fachwissen zu ermitteln. Ein sogenanntes „Korpus“ kann mittels der öffentlich verfügbaren Datenbank „PubMed“ unter Verwendung von „Natural Language Processing“ (NLP) erzeugt werden. Die weitere Systemanalyse und -visualisierung liefert ein Mengengerüst, eine Übersicht über die markantesten Forscherinnen und Forscher, die relevantesten Fachzeitschriften sowie die wichtigsten und möglicherweise präzisesten Behandlungsmöglichkeiten. Mit diesem Fachartikel wird demonstriert, wie auf eine relativ einfache Art und Weise die erste Literaturgrundlage zur Untersuchung von Behandlungsmöglichkeiten der Krankheit „Colitis Ulcerosa“ erstellt werden kann.
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsNotes
- 1.
https://www.ncbi.nlm.nih.gov/pubmed/ zuletzt abgerufen am 28.10.19.
- 2.
https://www.mendeley.com/ zuletzt abgerufen am 28.10.19.
- 3.
https://rapidminer.com/zuletzt abgerufen am 28.10.19.
- 4.
https://gephi.org/zuletzt abgerufen am 28.10.19.
- 5.
https://www.awmf.org/awmf-online-das-portal-der-wissenschaftlichen-medizin/awmf-aktuell.html zuletzt abgerufen am 28.10.2019.
Literatur
Basso, P. J., Saraiva Câmara, N. O., & Sales-Campos, H. (2019). Microbial-based therapies in the treatment of inflammatory bowel disease – An overview of human studies. Front Pharmacologica, 9, 1–11. https://doi.org/10.3389/fphar.2018.01571.
Bressler, B., Marshall, J. K., Bernstein, C. N., et al. (2015). Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus. Gastroenterology, 148, 1035–1058.e3. https://doi.org/10.1053/j.gastro.2015.03.001.
Buchkremer, R., Demund, A., Ebener, S., et al. (2019). The application of artificial intelligence technologies as a substitute for reading and to support and enhance the authoring of scientific review articles. IEEE Access, 7, 65263–65276. https://doi.org/10.1109/ACCESS.2019.2917719.
Cai, T., Giannopoulos, A. A., Yu, S., et al. (2016). Natural language processing technologies in radiology research and clinical applications. Radiographics, 36, 176–191. https://doi.org/10.1148/rg.2016150080.
Cleveland Clinic. (2019). Bo Shen, MD | Cleveland Clinic. In: my.clevelandclinic.org.
Cohen, R. D., Yu, A. P., Wu, E. Q., et al. (2010). Systematic review: the costs of ulcerative colitis in Western countries. Alimentary Pharmacology & Therapeutics, 31, 693–707. https://doi.org/10.1111/j.1365-2036.2010.04234.x.
Cosnes, J., Gower-Rousseau, C., Seksik, P., & Cortot, A. (2011). Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology, 140, 1785–1794. https://doi.org/10.1053/j.gastro.2011.01.055.
Dignass, A., Eliakim, R., Magro, F., et al. (2012a). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. Revista de Gastroenterologia de Mexico, 79, 263–289.
Dignass, A., Lindsay, J. O., Sturm, A., et al. (2012b). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. Journal of Crohn’s and Colitis, 6, 991–1030. https://doi.org/10.1016/j.crohns.2012.09.002.
Farkas, K., Rutka, M., Golovics, P. A., et al. (2016). Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. Journal of Crohn’s and Colitis, 10, 1273–1278. https://doi.org/10.1093/ecco-jcc/jjw085.
Favale, A., Onali, S., & Caprioli, F. et al. (2019). Comparative efficacy of vedolizumab and adalimumab in ulcerative colitis patients previously treated with infliximab. Inflamm Bowel Dis 1–10. https://doi.org/10.1093/ibd/izz057
Feagan, B. G., Chande, N., & MacDonald, J. K. (2013). Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. Inflammatory Bowel Diseases, 19, 2031–2040. https://doi.org/10.1097/MIB.0b013e3182920108.
Flamant, M., & Roblin, X. (2018). Inflammatory bowel disease: Towards a personalized medicine. Therapeutic Advances in Gastroenterology, 11
Gampfer, F., Jürgens, A., Müller, M., & Buchkremer, R. (2018). Past, current and future trends in enterprise architecture - A view beyond the horizon. Computers in Industry, 100, 70–84. https://doi.org/10.1016/j.compind.2018.03.006.
Høivik, M. L., Moum, B., Solberg, I. C., et al. (2013). Work disability in inflammatory bowel disease patients 10 years after disease onset: Results from the IBSEN study. Gut, 62, 368–375. https://doi.org/10.1136/gutjnl-2012-302311.
Järnerot, G., Hertervig, E., Friis-Liby, I., et al. (2005). Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology, 128, 1805–1811. https://doi.org/10.1053/j.gastro.2005.03.003.
Kelly, C. R., Ihunnah, C., Fischer, M., et al. (2014). Fecal microbiota transplant for treatment of clostridium difficile infection in immunocompromised patients. American Journal of Gastroenterology, 109, 1065–1071. https://doi.org/10.1038/ajg.2014.133.
Khanna, R., Jairath, V., Vande Casteele, N., et al. (2016). Efficient early drug development for ulcerative colitis. Gastroenterology, 150, 1056–1060. https://doi.org/10.1053/j.gastro.2016.03.013.
Kinugasa, T., & Akagi, Y. (2016). Status of colitis-associated cancer in ulcerative colitis. World Journal of Gastrointestinal Oncology, 8, 357. https://doi.org/10.4251/wjgo.v8.i4.351.
Lang, A., Salomon, N., Wu, J. C. Y., et al. (2015). Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clinical Gastroenterology and Hepatology, 13, 1444–1449.e1. https://doi.org/10.1016/j.cgh.2015.02.019.
Lewis, S. J., Gandomkar, Z., & Brennan, P. C. (2019). Artificial intelligence in medical imaging practice: Looking to the future. Journal of Medical Radiation Sciences. https://doi.org/10.1002/jmrs.369.
Loscalzo, J., & Barabasi, A. L. (2011). Systems biology and the future of medicine. Wiley Interdisciplinary Reviews Systems Biology and Medicine, 3, 619–627. https://doi.org/10.1002/wsbm.144.
Moayyedi, P., Surette, M. G., Kim, P. T., et al. (2015). Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology, 149, 102–109.e6. https://doi.org/10.1053/j.gastro.2015.04.001.
Mulder, C. J., Fockens, P., Meijer, J. W., et al. (1996). Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. European Journal of Gastroenterology and Hepatology, 8, 549–553.
Ng, S. C., Shi, H. Y., Hamidi, N., et al. (2017). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet, 390, 2769–2778. https://doi.org/10.1016/S0140-6736(17)32448-0.
Northwestern Medicine. (2019). Stephen B. Hanauer, MD | Northwestern Medicine. In: nm.org.
Paramsothy, S., Kamm, M., & Walsh, A. et al. (2016). OP017 Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: A randomised placebo-controlled trial.
Peyrin-Biroulet, L., Bressenot, A., & Kampman, W. (2014). Histologic remission: The ultimate therapeutic goal in ulcerative colitis? Clinical Gastroenterology and Hepatology, 12, 929–34.e2. https://doi.org/10.1016/j.cgh.2013.07.022.
Pravda, J. (2019). Can ulcerative colitis be cured? Discovery Medical, 27, 197–200.
RapidMiner incorporated. (2019). Lightning Fast Data Science Platform for Teams|RapidMiner©. In: rapidminer.com.
Reinisch, W., Sandborn, W. J., Hommes, D. W., et al. (2011). Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut, 60, 780–787. https://doi.org/10.1136/gut.2010.221127.
Rossen, N. G., Fuentes, S., van der Spek, M. J., et al. (2015). Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology, 149, 110–118.e4. https://doi.org/10.1053/j.gastro.2015.03.045.
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., et al. (2005). Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine, 353, 2462–2476. https://doi.org/10.1056/NEJMoa050516.
Sales-Campos, H., Basso, P. J., Alves, V. B. F., et al. (2015). Classical and recent advances in the treatment of inflammatory bowel diseases. Brazilian Journal of Medical and Biological Research, 48, 96–107.
Sandborn, W. J., Feagan, B. G., Marano, C., et al. (2014). Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology, 146, 85–95. https://doi.org/10.1053/j.gastro.2013.05.048.
Sandborn, W. J., Feagan, B. G., Wolf, D. C., et al. (2016). Ozanimod induction and maintenance treatment for ulcerative colitis. New England Journal of Medicine, 374, 1754–1762. https://doi.org/10.1056/NEJMoa1513248.
Sandborn, W. J., Ghosh, S., Panes, J., et al. (2012). Tofacitinib, an Oral Janus Kinase inhibitor, in active ulcerative colitis. New England Journal of Medicine, 367, 616–624. https://doi.org/10.1056/NEJMoa1112168.
Shortliffe, E. H. (2019). Artificial intelligence in medicine: Weighing the accomplishments, hype, and promise. Yearbook of Medical Informatics, 28, 257–262. https://doi.org/10.1055/s-0039-1677891.
Turner, D., Walsh, C. M., Steinhart, A. H., & Griffiths, A. M. (2007). Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression. Clinical Gastroenterology and Hepatology, 5, 103–110. https://doi.org/10.1016/j.cgh.2006.09.033.
UC San Diego Health. (2019). William Jeffery Sandborn, MD – Gastroenterology | UC San Diego Health. In: providers.ucsd.edu.
US National Library of Medicine (1996) PubMed – NCBI. In: ncbi.nlm.nih.gov.
Vanopstal, K., Buysschaert, J., Laureys, G., & Vander Stichele, R. (2013). Lost in PubMed. Factors influencing the success of medical information retrieval. Expert Systems with Applications, 40, 4106–4114. https://doi.org/10.1016/j.eswa.2013.01.036.
Vermeire, S., O’Byrne, S., Keir, M., et al. (2014). Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial. Lancet (London, England), 384, 309–318. https://doi.org/10.1016/S0140-6736(14)60661-9.
Viscido, A., Papi, C., Latella, G., & Frieri, G. (2019). Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics: Targets and Therapy, 13, 23–31.
Vogt, H., Hofmann, B., & Getz, L. (2016). The new holism: P4 systems medicine and the medicalization of health and life itself. Medicine, Health Care and Philosophy, 19, 307–323. https://doi.org/10.1007/s11019-016-9683-8.
Wong, D. J., Roth, E. M., Feuerstein, J. D., & Poylin, V. Y. (2019). Surgery in the age of biologics. Gastroenterology Reports, 7, 77–90.
Yamamoto-Furusho, J. K., Gutiérrez-Grobe, Y., López-Gómez, J. G., et al. (2018). Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Review Gastroenterology México, 83, 144–167. https://doi.org/10.1016/j.rgmx.2017.08.006.
Yamamoto, T., Iida, T., Ikeya, K., et al. (2018). A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clinical and Translational Gastroenterology, 9, 170. https://doi.org/10.1038/s41424-018-0037-0.
Yoshimura, N., Watanabe, M., Motoya, S., et al. (2015). Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology, 149, 1775–1783.e2. https://doi.org/10.1053/j.gastro.2015.08.044.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Fachmedien Wiesbaden GmbH, ein Teil von Springer Nature
About this chapter
Cite this chapter
Boichak, O., Buchkremer, R. (2020). Die Anwendung von Natural Language Processing zur kompakten Erfassung einer Krankheit. In: Buchkremer, R., Heupel, T., Koch, O. (eds) Künstliche Intelligenz in Wirtschaft & Gesellschaft. FOM-Edition. Springer Gabler, Wiesbaden. https://doi.org/10.1007/978-3-658-29550-9_22
Download citation
DOI: https://doi.org/10.1007/978-3-658-29550-9_22
Published:
Publisher Name: Springer Gabler, Wiesbaden
Print ISBN: 978-3-658-29549-3
Online ISBN: 978-3-658-29550-9
eBook Packages: Business and Economics (German Language)